Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
4.310
-1.060 (-19.74%)
At close: Apr 10, 2026, 4:00 PM EDT
4.389
+0.079 (1.83%)
After-hours: Apr 10, 2026, 7:04 PM EDT
Harvard Bioscience Revenue
In the year 2025, Harvard Bioscience had annual revenue of $86.55M, down -8.06%. Harvard Bioscience had revenue of $23.74M in the quarter ending December 31, 2025, a decrease of -3.34%.
Revenue (ttm)
$86.55M
Revenue Growth
-8.06%
P/S Ratio
0.22
Revenue / Employee
$255,310
Employees
339
Market Cap
19.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 86.55M | -7.59M | -8.06% |
| Dec 31, 2024 | 94.14M | -18.12M | -16.14% |
| Dec 31, 2023 | 112.25M | -1.09M | -0.96% |
| Dec 31, 2022 | 113.34M | -5.57M | -4.68% |
| Dec 31, 2021 | 118.90M | 16.80M | 16.46% |
| Dec 31, 2020 | 102.10M | -14.08M | -12.12% |
| Dec 31, 2019 | 116.18M | -4.60M | -3.81% |
| Dec 31, 2018 | 120.77M | 43.37M | 56.02% |
| Dec 31, 2017 | 77.41M | -27.11M | -25.94% |
| Dec 31, 2016 | 104.52M | -4.14M | -3.81% |
| Dec 31, 2015 | 108.66M | 1,000.00 | - |
| Dec 31, 2014 | 108.66M | 3.49M | 3.32% |
| Dec 31, 2013 | 105.17M | -6.00M | -5.40% |
| Dec 31, 2012 | 111.17M | 2.31M | 2.12% |
| Dec 31, 2011 | 108.86M | 685.00K | 0.63% |
| Dec 31, 2010 | 108.18M | 22.41M | 26.12% |
| Dec 31, 2009 | 85.77M | -2.28M | -2.59% |
| Dec 31, 2008 | 88.05M | 4.64M | 5.57% |
| Dec 31, 2007 | 83.41M | 7.23M | 9.49% |
| Dec 31, 2006 | 76.18M | 8.75M | 12.98% |
| Dec 31, 2005 | 67.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Retractable Technologies | 38.27M |
| Bionano Genomics | 28.51M |
| Precision Optics Corporation | 24.42M |
| Jin Medical International | 20.69M |
| Nephros | 18.79M |
| Ekso Bionics Holdings | 12.80M |
| Milestone Scientific | 8.97M |
| Lucyd | 2.66M |
HBIO News
- 4 weeks ago - Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Harvard Bioscience Announces Reverse Stock Split - GlobeNewsWire
- 5 weeks ago - Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum - GlobeNewsWire
- 6 weeks ago - Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET - GlobeNewsWire
- 2 months ago - Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas - GlobeNewsWire
- 2 months ago - Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth - GlobeNewsWire
- 4 months ago - Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package - GlobeNewsWire
- 5 months ago - Harvard Bioscience Announces Third Quarter 2025 Financial Results - GlobeNewsWire